TISIDB

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF00250 Forkhead domain
Function	Transcriptional factor regulating the expression of cell cycle genes essential for DNA replication and mitosis. Plays a role in the control of cell proliferation. Plays also a role in DNA breaks repair participating in the DNA damage checkpoint response.

> Gene Ontology [ TOP ]
Biological Process	GO:0000086 G2/M transition of mitotic cell cycle GO:0001933 negative regulation of protein phosphorylation GO:0006282 regulation of DNA repair GO:0006302 double-strand break repair GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0007050 cell cycle arrest GO:0007265 Ras protein signal transduction GO:0007568 aging GO:0007569 cell aging GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031098 stress-activated protein kinase signaling cascade GO:0032872 regulation of stress-activated MAPK cascade GO:0032873 negative regulation of stress-activated MAPK cascade GO:0042326 negative regulation of phosphorylation GO:0042770 signal transduction in response to DNA damage GO:0042772 DNA damage response, signal transduction resulting in transcription GO:0043409 negative regulation of MAPK cascade GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044839 cell cycle G2/M phase transition GO:0045739 positive regulation of DNA repair GO:0045786 negative regulation of cell cycle GO:0046578 regulation of Ras protein signal transduction GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051056 regulation of small GTPase mediated signal transduction GO:0051403 stress-activated MAPK cascade GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070303 negative regulation of stress-activated protein kinase signaling cascade GO:0071156 regulation of cell cycle arrest GO:0072331 signal transduction by p53 class mediator GO:0072593 reactive oxygen species metabolic process GO:0090342 regulation of cell aging GO:0090344 negative regulation of cell aging GO:1902532 negative regulation of intracellular signal transduction GO:2000377 regulation of reactive oxygen species metabolic process GO:2000779 regulation of double-strand break repair GO:2000781 positive regulation of double-strand break repair GO:2001020 regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-69273: Cyclin A/B1 associated events during G2/M transition R-HSA-69275: G2/M Transition R-HSA-453274: Mitotic G2-G2/M phases R-HSA-156711: Polo-like kinase mediated events

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FOXM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FOXM1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
22139074	Lung Carcinoma	Inhibit immunity	Ablation of Foxm1 in macrophages reduced the number and size of lung tumors in macFoxm1(-/-) mice. The expression levels of the pro-inflammatory genes iNOS, Cox-2, interleukin-1b (IL-1b) and IL-6, as well as the migration-related genes macrophage inflammatory protein-1 (MIP-1α), MIP-2 and MMP-12, were decreased in macrophages isolated from macFoxm1(-/-) mice. The chemokine receptors responsible for monocyte recruitment to the lung, CX(3)CR1 and CXCR4, were decreased in Foxm1-deficient monocytes. In co-transfection experiments, Foxm1 directly bound to and transcriptionally activated the CX(3)CR1 promoter. Expression of Foxm1 in macrophages is required for pulmonary inflammation, recruitment of macrophages into tumor sites and lung tumor growth.

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FOXM1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.66	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FOXM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.419	0.236
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.357	0.846
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.466	0.738
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.662	0.128
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.055	0.581
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.178	0.948
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.17	0.677
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.258	0.86
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.724	0.633
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.013	0.992
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.243	0.89
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.525	0.000243

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FOXM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXM1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FOXM1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FOXM1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FOXM1
Name	forkhead box M1
Aliases	HFH-11; trident; HNF-3; INS-1; MPHOSPH2; TGT3; M-phase phosphoprotein 2; FKHL16; FKHL16B; HFH11; MPP-2; PIG2 ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FOXM1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FOXM1